536 results on '"Bibeau, Frédéric"'
Search Results
2. Réseau RENAPE : vers une meilleure équité d’accès aux soins et à l’expertise pour les patients atteints de cancers rares du péritoine
3. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts
4. Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR)
5. Evaluation of immune infiltrate according to the HER2 status in colorectal cancer
6. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study
7. Réseau RENAPE : vers une meilleure équité d’accès aux soins et à l’expertise pour les patients atteints de cancers rares du péritoine
8. The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases
9. Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)
10. Prevalence and significance of HPV DNA detection below the clinical threshold of the commercial kit Alinity m HR‐HPV assay (Abbott)
11. Les dépôts tumoraux (DT), un critère pronostique péjoratif probablement sous-estimé, à prendre en compte dans la prise en charge thérapeutique des malades atteints de cancer colique de stade III
12. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
13. Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)
14. Peritoneal metastases of unknown primary with hepatoid features
15. Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients
16. Les cancers colorectaux héréditaires vus par le pathologiste
17. Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients
18. Biobanques tumorales et gestion des données complexes : enjeux actuels et futurs
19. Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival
20. The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis
21. Validated and promozing biomarkers in oesogastric cancers
22. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma
23. FREGAT : base clinicobiologique nationale française dédiée à la recherche sur les cancers œsogastriques
24. EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes
25. Abstract 5430: Improved colorectal cancer survival prediction with deep learning-based WSI analysis on PETACC8 and PRODIGE13 cohorts
26. Supplementary Tables 1-7 from Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer
27. Data from Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer
28. Supplementary Figures 1-4 from Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer
29. Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
30. Biomarqueurs prédictifs de l’efficacité des inhibiteurs de checkpoint immunitaire dans le traitement des cancers
31. Réponse immune et cancers digestifs : implications pronostiques et thérapeutiques
32. Supplementary Figure 5 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
33. Supplementary Figures from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
34. Supplementary Figure 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
35. Supplementary Figure 4 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
36. Data from Snail and Slug Play Distinct Roles during Breast Carcinoma Progression
37. Supplementary Figure 1 from Snail and Slug Play Distinct Roles during Breast Carcinoma Progression
38. supplementary methods from Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer
39. Supplementary Figure 2 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
40. supplementary figures 1 to 13 and supplementary tables 1 to 4 from Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer
41. Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
42. Supplementary Figure 1 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
43. Supplementary Materials and Methods, Figure Legends, Tables 1 - 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
44. Supplementary Figures 2-3 from Snail and Slug Play Distinct Roles during Breast Carcinoma Progression
45. Supplementary Tables 2-3 from Snail and Slug Play Distinct Roles during Breast Carcinoma Progression
46. Supplementary Data from A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer
47. SALL4 ‐related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features
48. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?
49. Métastases révélatrices de mésothéliomes malins du péritoine : difficultés diagnostiques à propos de deux cas et conduite à tenir
50. Biomarqueurs actuels et à venir dans les cancers œsogastriques.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.